Market News Latest

Lupus Nephritis Market to Witness Upsurge in Growth During the Forecast Period 2030 | Key Companies – Roche, Novartis, AstraZeneca, Boehringer Ingelheim, and Several Others

 Breaking News
  • No posts were found

Lupus Nephritis Market to Witness Upsurge in Growth During the Forecast Period 2030 | Key Companies – Roche, Novartis, AstraZeneca, Boehringer Ingelheim, and Several Others

October 29
05:40 2021
Lupus Nephritis Market to Witness Upsurge in Growth During the Forecast Period 2030 | Key Companies - Roche, Novartis, AstraZeneca, Boehringer Ingelheim, and Several Others
Delveinsight Business Research LLP
DelveInsight’s “Lupus Nephritis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Lupus Nephritis Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Lupus Nephritis market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Lupus Nephritis Market

Lupus Nephritis: An Overview

Lupus nephritis (LN) is a common and potentially devastating manifestation of SLE. It is a leading cause of morbidity and mortality in patients with SLE. LN leads to inflammation of small blood vessels which play an important role in filtering waste materials in the kidney. It also involves the inflammation of glomeruli. Although LN can occur during a flare of SLE with skin manifestations or other organ system involvement, it often occurs without other clinical signs of active lupus.

Lupus Nephritis Market Key Facts

  • As per DelveInsight’s estimates, the total prevalent population of Lupus Nephritis in the 7 major markets was 192,016 in 2018.

  • As per a study by McDonald L. et al., titled “Identifying Patients With Lupus Nephritis in the United Kingdom Clinical Practice Research Datalink”, (2017), recent data suggest the prevalence of SLE in the UK is 97 per 100 000, with 86% of observed cases being female. It is thought that the prevalence of LN in SLE patients is between 20-60%.

  • A study by Delarche A. et al., titled “Incidence and outcome of lupus nephritis in French Polynesia”, (2018) stated that the annual incidence of SLE and LN in French Polynesia was 3.6 and 0.96 per 100,000, respectively.

Get FREE sample copy at: Lupus Nephritis Therapeutics Market

Key Benefits of Lupus Nephritis Market Report

  • The report provides an in-depth analysis of Lupus Nephritis Market Size and Share till 2030 in the seven major markets.

  • The report will help in developing business strategies by understanding the Lupus Nephritis Market Trends, key players, and ongoing developments that shape and drive the market growth in the upcoming years.

  • It covers Lupus Nephritis current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.

  • The report provides a detailed assessment of the Lupus Nephritis market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Lupus Nephritis Market

Lupus Nephritis Market size is expected to increase during the forecast period owing to the launch of upcoming therapies, extensive research and development in the domain, rising awareness, among others.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Lupus Nephritis market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Lupus Nephritis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Lupus Nephritis Epidemiology

The epidemiology section covers insights about the historical and current Lupus Nephritis patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Lupus Nephritis Epidemiology Segmentation

  • Prevalent Population 

  • Gender-Specific Prevalent Population

  • Clinical Manifestations of Lupus Nephritis

  • Total Diagnosed Population

  • Class- Specific cases

Lupus Nephritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Lupus Nephritis market or expected to get launched in the market during the study period. The analysis covers Lupus Nephritis market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Lupus Nephritis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Lupus Nephritis Therapeutics Assessment

Key companies in the Lupus Nephritis Market include:

  • Roche

  • Novartis

  • AstraZeneca

  • Boehringer Ingelheim

And many others

Lupus Nephritis Therapies covered in the report include:

  • GAZYVA (Obinutuzumab; GA-101)

  • Anifrolumab (formerly MEDI-546)

  • BI 655064

  • Iscalimab

And many others

Overall, the increasing prevalence of Lupus Nephritis assisted by organizational support along with the predicted approval of several promising emerging therapies, which are currently under late-stage development is expected to fuel the market size during the forecasted period of 2021–2030.

Request for Sample @ Lupus Nephritis Emerging Therapies and Key Companies

Table of Content

1. Key Insights

2. Executive Summary 

3. Lupus Nephritis Competitive Intelligence Analysis

4. Lupus Nephritis Market Overview at a Glance

5. Lupus Nephritis Disease Background and Overview

6. Lupus Nephritis Patient Journey

7. Lupus Nephritis Epidemiology and Patient Population

8. Lupus Nephritis Treatment Algorithm, Current Treatment, and Medical Practices

9. Lupus Nephritis Unmet Needs

10. Key Endpoints of Lupus Nephritis Treatment

11. Lupus Nephritis Marketed Products

12. Lupus Nephritis Emerging Therapies

13. Lupus Nephritis Seven Major Market Analysis

14. Attribute Analysis

15. Lupus Nephritis Market Outlook (7 major markets)

16. Lupus Nephritis Access and Reimbursement Overview

17. KOL Views on the Lupus Nephritis Market.

18. Lupus Nephritis Market Drivers

19. Lupus Nephritis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/lupus-nephritis-market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/